Cara Therapeutics, Inc. (NASDAQ:CARA) Short Interest Update

Cara Therapeutics, Inc. (NASDAQ:CARA) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 576,700 shares, a decrease of 54.2% from the November 15th total of 1,260,000 shares. Based on an average daily trading volume, of 541,600 shares, the short-interest ratio is presently 1.1 days. Approximately 1.3% of the shares of the stock are sold short.

Cara Therapeutics Price Performance

NASDAQ CARA traded up $0.00 on Friday, reaching $0.26. The company had a trading volume of 1,006,388 shares, compared to its average volume of 638,491. The business has a 50 day moving average of $0.29 and a two-hundred day moving average of $0.34. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.31. The firm has a market cap of $14.37 million, a price-to-earnings ratio of -0.15 and a beta of 0.64.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Cara Therapeutics in a report on Saturday, December 7th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $2.32.

Institutional Trading of Cara Therapeutics

A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in Cara Therapeutics during the 3rd quarter worth about $29,000. FMR LLC grew its holdings in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares during the period. Finally, Disciplined Growth Investors Inc. MN grew its holdings in Cara Therapeutics by 6.6% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares during the period. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.